Resources from the same session
5475 - Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
Presenter: Kevin Harrington
Session: Poster Discussion session - Developmental therapeutics / investigational immunotherapy
Resources:
Abstract
5967 - Phase 1/2, Multicenter, Open-Label Study of Intratumoral/Intralesional Administration of the Retinoic Acid–Inducible Gene I (RIG-I) Activator MK-4621 in Patients With Advanced or Recurrent Tumors
Presenter: Mark Middleton
Session: Poster Discussion session - Developmental therapeutics / investigational immunotherapy
Resources:
Abstract
3099 - Clinical activity, safety, and PK/PD from a Phase 1 study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)
Presenter: Ignacio Melero
Session: Poster Discussion session - Developmental therapeutics / investigational immunotherapy
Resources:
Abstract
4732 - Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma
Presenter: Matthew Krebs
Session: Poster Discussion session - Developmental therapeutics / investigational immunotherapy
Resources:
Abstract
Poster Discussion session - Developmental therapeutics / investigational immunotherapy - Invited Discussant LBA15, LBA16, 412PD and 413PD
Presenter: Maria Grazia Daidone
Session: Poster Discussion session - Developmental therapeutics / investigational immunotherapy
Resources:
Slides
Webcast
4575 - Phase 1 Study of the CTLA-4 Inhibitor MK-1308 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Presenter: Byoung Chul Cho
Session: Poster Discussion session - Developmental therapeutics / investigational immunotherapy
Resources:
Abstract
1926 - Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors.
Presenter: Jacques Medioni
Session: Poster Discussion session - Developmental therapeutics / investigational immunotherapy
Resources:
Abstract
4827 - Final Results from a Phase I Clinical Trial Evaluating the Safety, Immunogenicity, and Anti-Tumor Activity of SNS-301 in Men with Biochemically Relapsed Prostate Cancer
Presenter: Luke Nordquist
Session: Poster Discussion session - Developmental therapeutics / investigational immunotherapy
Resources:
Abstract
1756 - Combination Therapy Optimization in Gastrointestinal Cancers using Multi-omic Molecular Profiling
Presenter: M. Cecilia Monge Bonilla
Session: Poster Discussion session - Developmental therapeutics / investigational immunotherapy
Resources:
Abstract
4362 - NCI-MATCH Arms N & P: phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss
Presenter: Filip Janku
Session: Poster Discussion session - Developmental therapeutics / investigational immunotherapy
Resources:
Abstract